Abstract:
Introduction
• Recent studies have shown that acetazolamide is a potent cerebral vasodilator in both counteracted the cerebral vasoconstricting effect of hyperoxia, but also increased markedly the cerebral blood flow and oxygen delivery to the brain. 6 These experimental findings suggest that the combination of hyperbaric oxygenation and acetazolamide may be of therapeutic value in patients with cerebral ischemic disorders. This study was designed to test this possibility. Transient cerebral ischemia was induced in normal young subjects by brief periods of hypocapnia and hypotension produced by vigorous hyperventilation and Valsalva maneuver. The effects of acetazolamide and hyperbaric oxygenation as well as their combination were studied in these subjects to determine whether these measures could preserve cerebral function under such adverse conditions.
Methods
Seven healthy male volunteer subjects between the ages of 18 and 25 years were studied in fasting state. The study was carried out on a tilt table in the hyperbaric chamber. Inspiratory gas consisting of room air, 9% or 100% oxygen was administered via a special plastic head tent placed over the subject's head and shoulders. This plastic head tent permitted the subject's face to be observed throughout the study and the gas mixtures to be easily changed. Twelve electroencephalographic electrodes were attached to the scalp of each subject in a bilateral anteroposterior configuration and the electroencephalogram recorded on an eight-channel Grass unit. An indwelling Teflon needle was placed in the left brachial artery and arterial blood pressures were measured with a Statham strain gauge and recorded on a Gilson polygraphic recorder.
With the subject in a 40° head-up tilt position, syncope was induced by hyperventilation for one minute followed by a 10-second vigorous Valsalva maneuver. Baseline observations were made of the electroencephalogram, electrocardiogram and arterial blood pressure, all of which were continuously recorded during the hyperventilation and Valsalva maneuver and during the immediate postsyncopal period. Arterial blood samples were obtained at the end of each hyperventilation period and just before the Valsalva maneuver. Arterial pH, pO 2 and pCO 2 were determined immediately with an IL Instrument in the hyperbaric chamber. In order to detect and record the changes in consciousness, a series of random numbers were read to the subject who was instructed to respond to the even numbers by pressing an electrical marker. Signals from this marker were continuously recorded 70 along with the other physiological measurements during the Valsalva maneuver. The development of syncope was determined by the subject's inability to respond to the auditory stimuli, the appearance of characteristic high-voltage slow wave activity in the electroencephalograms, and the subject's lack of recall for the events associated with the end of the Valsalva maneuver.
After practicing the procedures for several times before the study, each subject was instructed to perform three hyperventilation-Valsalva maneuvers during each of the following four experimental conditions: (1) 15 minutes after intravenous administration of 10 ml of saline solution (used as a placebo) while breathing room air at normal atmospheric pressure; (2) 
Results
An example of the physiological recordings during a typical syncopal reaction induced by hyperventilation-Valsalva maneuver at ambient environment is shown in figure 1 . Starting from the top, there are records of electroencephalogram, two-second time signals, arterial blood pressure, signals indicating the subject's finger movements in response to the verbal cues, electrocardiogram, and the duration of the Valsalva maneuver. After one minute of hyperventilation, Subject A. B. had an arterial pO 2 of 125 mm Hg, and a reduction of arterial pCO 2 to 25 mm Hg. When the mean arterial blood pressure fell to the level of 63 mm Hg, the subject fainted and failed to respond to verbal cues. At the same time, high-amplitude slow waves appeared diffusely in the electroencephalogram confirming the occurrence of syncope.
The effects of acetazolamide and hyperbaric oxygenation in preventing syncope induced by the hyperventilation-Valsalva maneuver are illustrated in figure 2. The same physiological parameters were recorded during a hyperventilation-Valsalva maneuver by the tions. As shown in figure 3 , when the subjects were breathing room air at ambient pressure or 9% oxygen at 2.36 atmospheres ("air equivalent"), hyperventilation-Valsalva maneuver almost always produced syncope in every subject. The combination of hyperbaric oxygenation and acetazolamide prevented the The over-all incidence of syncope which resulted from the hyperventilation-Valsalva maneuvers performed in different experimental conditions in all seven subjects. 
FIGURE 5
The syncope in four of seven subjects and reduced the frequency of syncope in another subject (S. M.). In one of the subjects (V. P.) syncopal episodes were also completely prevented by hyperbaric oxygenation alone. In the remaining two of the seven subjects neither the hyperbaric oxygenation nor its combination with acetazolamide provided a protective effect.
The over-all incidence of syncope resulting from the hyperventilation-Valsalva maneuvers is shown in figure 4 . In each experimental condition, a total of 21 hyperventilationValsalva maneuvers were performed by seven subjects. In ambient environment, 19 of 21 (91%) hyperventilation-Valsalva maneuvers produced loss of consciousness. Similar results were obtained when the subjects were breathing 9% oxygen at 2.36 atmospheric pressure during which 18 of the 21 (86%) attempts resulted in syncope. Hyperbaric oxygenation alone seemed to have some protective effect; and syncope only occurred in 14 of 21 (67% ) hyperventilation-Valsalva maneuvers. The greatest reduction in the incidence of syncope was observed after the subject had re-
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ceived intravenously 500 mg of acetazolamide under hyperbaric oxygenation. At this time only 7 of 21 (33%) hyperventilation-Valsalva maneuvers resulted in syncope.
The critical levels of mean arterial blood pressure and arterial pCO 2 below which syncope could be induced are shown in figure  5 . In ambient environment, syncope almost always occurred when the arterial pCO 2 levels fell below 26 mm Hg and the mean blood pressure below 90 mm Hg. These critical levels were not significantly changed by increased atmospheric pressure or by hyperbaric oxygenation alone. However, with the combination of hyperbaric oxygenation and acetazolamide, syncope did not occur until the mean arterial blood pressure fell below the level of 64 mm Hg and the arterial pCO 2 below 26 mm Hg.
Discussion
Hyperbaric oxygenation produces a very high oxygen tension in the arterial blood and would be expected to increase oxygen delivery to the brain. For this reason, hyperbaric oxygenation has been used in the treatment of patients with cerebral arterial occlusive disease. 8 The vasoconstricting effect of oxygen, however, produces a decrease in cerebral blood flow 7 "
9 and may reduce availability of various substrates to the brain. The possible beneficial effects of hyperbaric oxygen therapy are thus limited. In order to counteract the vasoconstricting effect of hyperoxia, it has been suggested that cerebral vasodilating agents be administered concomitantly with hyperbaric therapy. One such cerebral vasodilator is acetazolamide, an inhibitor of carbonic anhydrase. This agent has been found to increase the total cerebral blood flow in humans with or without cerebrovascular disease by as much as 60 to 110%. 1 -1 When administered to experimental animals under hyperbaric oxygenation, acetazolamide not only counteracted the cerebral vasoconstricting effect of oxygen, but also produced a significant increase in both fast and slow components of cerebral blood flow as measured by radioactive xenon techniques. 6 With the concomitant increase in arterial oxygen tension, the calculated oxygen delivery to the brain was also significantly increased.
This study evaluates the possible protective effects of acetazolamide and hyperbaric oxygenation on one form of syncope (the socalled "fainting lark") induced by byperventiSfroke, Vol. I, March-April 1970 lation and a forceful Valsalva maneuver. The loss of consciousness caused by the "fainting lark" is mainly related to: (1) the reduction of cerebral perfusion caused by a sudden decrease in systemic blood pressure at the end of the Valsalva maneuver 10 and (2) the cerebral vasoconstriction due to hypocapnia secondary to hyperventilation. 11 A third factor which may contribute to the reduction in cerebral circulation is the secondary elevation in pressure within the cranial cavity which is transmitted via the venous system from the increased intrathoracic and intra-abdominal pressures during the Valsalva maneuver. 12 The combination of all three factors usually produce sufficient reduction in cerebral perfusion to induce loss of consciousness. The findings in this study indicate that the incidence of syncope can be reduced by hyperbaric oxygenation alone or in combination with acetazolamide. It was likewise found that the critical level of the mean arterial blood pressure necessary for inducing loss of consciousness was also decreased by the combination of hyperoxia and acetazolamide. When compared with their responses during the control period, the subjects receiving acetazolamide during hyperbaric oxygenation were able to tolerate more severe degrees of hypotension before losing consciousness.
In a previous study, 18 the inhalation of 100% oxygen at ambient atmospheres was found to have no effect in preventing this form of syncope, but instead may have facilitated the development of loss of consciousness in some subjects. Inhalation of 100% oxygen at 2.36 atmospheres of pressure in the present study seemed to reduce the incidence of syncope as compared to the responses during the control period or during inhalation of the "air equivalent" (i.e., 9% oxygen at 2.36 atmospheric pressure). It seems likely that hyperbaric oxygenation alone may produce sufficient increase in oxygen delivery to the brain to overcome the ischemia due to vasoconstricting effects of oxygen.
The exact mechanism by which acetazolamide increases cerebral blood flow is not entirely clear. The administration of acetazolamide has been found to increase tissue pCO 2 in the brain. 8 -14 ' ls By inhibiting carbonic anhydrase, acetazolamide apparently delays the conversion of free carbon dioxide into bicarbonate in erythrocytes and impairs the carbon
